Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen

FC Moazedi-FuerstDivision of Rheumatology and Immunology, Medical University of Graz, AustriaCorrespondence[email protected]

SM KielhauserDivision of Rheumatology and Immunology, Medical University of Graz, Austria

K BrickmannDivision of Rheumatology and Immunology, Medical University of Graz, Austria

J HermannDivision of Rheumatology and Immunology, Medical University of Graz, Austria

A LutfiDepartment of Radiology, Medical University of Graz, Austria

M MeilingerDivision of Pulmonology, Medical University of Graz, Austria

HP BrezinschekDivision of Rheumatology and Immunology, Medical University of Graz, Austria

WB GraningerDivision of Rheumatology and Immunology, Medical University of Graz, Austria

show all

References

Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578–83.
PubMed Web of Science ®Google Scholar
Bredemeier M, de Oliveira FK, Rocha CM. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). Published online: 27 August 2013. doi: 10.1002/acr.22116.
Google Scholar
Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010;49:271–80.
PubMed Web of Science ®Google Scholar
Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;30:S17–22.
PubMed Web of Science ®Google Scholar
Diot E, Boissinot E, Asquier E, Guilmot JL, Lemarie E, Valat C Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest 1998;114:1623–9.
PubMed Web of Science ®Google Scholar
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–81.
PubMed Web of Science ®Google Scholar
Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010;40:127–36.
PubMed Web of Science ®Google Scholar

Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date